天新药业
(603235)
| 流通市值：112.07亿 | | | 总市值：112.07亿 |
| 流通股本：4.38亿 | | | 总股本：4.38亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 639,757,715.06 | 2,345,041,106.85 | 1,630,945,301.49 | 1,122,350,298.53 |
| 营业收入 | 639,757,715.06 | 2,345,041,106.85 | 1,630,945,301.49 | 1,122,350,298.53 |
| 二、营业总成本 | 475,317,848.85 | 1,674,686,700.99 | 1,105,745,608.76 | 710,909,338.89 |
| 营业成本 | 383,907,746.21 | 1,352,810,758.68 | 891,446,362.73 | 585,514,347.36 |
| 税金及附加 | 10,739,135.5 | 28,523,269.58 | 20,482,624.99 | 11,416,757.77 |
| 销售费用 | 10,326,442.36 | 37,204,806.32 | 26,950,112.5 | 19,847,242.95 |
| 管理费用 | 39,133,362.89 | 180,919,287.5 | 123,484,398.3 | 77,512,431.8 |
| 研发费用 | 20,631,353.16 | 100,523,913.9 | 71,324,408.74 | 42,459,796.68 |
| 财务费用 | 10,579,808.73 | -25,295,334.99 | -27,942,298.5 | -25,841,237.67 |
| 其中:利息费用 | 9,942,636.95 | 8,156,526.69 | 5,465,461.32 | 3,973,907.09 |
| 其中:利息收入 | 7,350,665.96 | 37,390,890.55 | 27,283,093.21 | 17,480,303.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 465,538.02 | 465,538.02 |
| 加:投资收益 | 1,724,092.69 | 8,927,337.52 | 6,155,700.75 | 4,121,010.46 |
| 资产处置收益 | - | -505,168.85 | -10,296.4 | -10,296.5 |
| 资产减值损失(新) | - | -17,342,319.31 | -14,003,597.41 | -14,004,087.93 |
| 信用减值损失(新) | -749,257.98 | -421,800.99 | 2,922,880.98 | 1,044,634.2 |
| 其他收益 | 11,403,511.51 | 44,300,991.71 | 32,531,977.98 | 22,171,901.58 |
| 四、营业利润 | 176,818,212.43 | 705,313,445.94 | 553,261,896.65 | 425,229,659.47 |
| 加:营业外收入 | 28,426.34 | 1,926,054.46 | 969,826.46 | 438,110.31 |
| 减:营业外支出 | 98,250.99 | 2,817,518.94 | 2,586,643.3 | 1,078,229.52 |
| 五、利润总额 | 176,748,387.78 | 704,421,981.46 | 551,645,079.81 | 424,589,540.26 |
| 减:所得税费用 | 29,744,782.7 | 112,843,070.35 | 91,341,203.68 | 68,575,990.96 |
| 六、净利润 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 | 356,013,549.3 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 | 356,013,549.3 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 | 356,013,549.3 |
| 扣除非经常损益后的净利润 | 136,835,514.96 | 551,073,118.63 | 430,953,785.84 | 336,278,264.05 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.34 | 1.35 | 1.06 | 0.82 |
| (二)稀释每股收益 | 0.34 | 1.35 | 1.06 | 0.82 |
| 九、综合收益总额 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 | 356,013,549.3 |
| 归属于母公司股东的综合收益总额 | 147,003,605.08 | 591,578,911.11 | 460,303,876.13 | 356,013,549.3 |
| 公告日期 | 2026-04-30 | 2026-04-24 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |